Guan Yelan, Xu Feiqi, Zheng Shuai, Gu Xiaodong, Sun Yan
Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Postgraduate training base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Discov Oncol. 2023 Jun 20;14(1):106. doi: 10.1007/s12672-023-00720-4.
This study aimed to construct a nomogram to effectively predict the 3 years and 5 years overall survival of patients with thymic squamous cell carcinoma (TSCC).
From 2000 to 2019, a total of 355 patients with TSCC were enrolled in our research from the Surveillance, Epidemiology, and End Results (SEER) database and used as the training cohort. 106 patients were included from the Zhejiang Cancer Hospital, for the external validation cohort. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index and curve of calibration. The two cohorts were divided into low-risk and high-risk subgroups based on the median risk score.
Age (p = 0.002), stage (p = 0.003), surgery therapy (p < 0.001), and radiotherapy (p = 0.030) were the independent prognostic factors for overall survival and were incorporated in the prognostic model. The discrimination of the nomogram revealed a good prognostic accuracy and clinical applicability as indicated by C-index values of 0.696 (95% confidence interval [CI] 0.676-0.716) and 0.717 (95% CI 0.640-0.794) for the training cohort and external validation cohort, respectively. In addition, the two cohorts were divided into a high-risk group and a low-risk group according to the median risk score. Significant differences in overall survival were observed between the high-risk and low-risk groups in the training (p < 0.0001) and external validation cohort (p < 0.0001).
We developed a nomogram to predict 3- and 5 year survival rate for TSCC. This nomogram provides a convenient and reliable tool for assessing the condition of patients with TSCC and assisting clinicians in making decisions.
本研究旨在构建一种列线图,以有效预测胸腺鳞状细胞癌(TSCC)患者的3年和5年总生存率。
2000年至2019年,我们从监测、流行病学和最终结果(SEER)数据库中纳入了355例TSCC患者作为训练队列。从浙江省肿瘤医院纳入106例患者作为外部验证队列。使用Cox比例风险回归模型,基于影响预后的危险因素构建列线图。通过C指数和校准曲线评估列线图的区分度和校准度。根据中位风险评分将两个队列分为低风险和高风险亚组。
年龄(p = 0.002)、分期(p = 0.003)、手术治疗(p < 0.001)和放疗(p = 0.030)是总生存的独立预后因素,并纳入预后模型。列线图的区分度显示出良好的预后准确性和临床适用性,训练队列和外部验证队列的C指数值分别为0.696(95%置信区间[CI] 0.676 - 0.716)和0.717(95% CI 0.640 - 0.794)。此外,根据中位风险评分将两个队列分为高风险组和低风险组。训练队列(p < 0.0001)和外部验证队列(p < 0.0001)的高风险组和低风险组之间总生存存在显著差异。
我们开发了一种列线图来预测TSCC的3年和5年生存率。该列线图为评估TSCC患者病情和协助临床医生决策提供了一种方便可靠的工具。